Analyse de l'application AHFS Drug Information pour le 18 avril

"Try before you buy" - Download the FREE App, which includes sample content. In-App purchase required to unlock all content. AHFS® Drug Information™ - Doody's Core Title - is your comprehensive, interactive treatment and drug therapy solution - complete with therapeutic guidelines and off-label uses. 2020, 2021, 2022, 2023, 2024,2025 Doody's Core Titles List Selection AHFS Drug Information® 2026 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses. With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice. With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice. Updates in the new edition: - Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines - Expanded coverage of specialty medications used to treat a variety of complex, chronic conditions that often require special handling and administration and may require careful - oversight to manage severe adverse effects and dosage adjustments - Contemporary topics such as biosimilars, novel orphan drugs, and updated vaccine guidance based on recommendations from the CDC’s Advisory Committee on Immunization Practices (ACIP) and other authoritative organizations - Essential drug information content for patient safety including FDA Medwatch alerts, Standardize4Safety concentrations for IV and oral liquid medications, ISMP recommendations, REMS data, BEERS criteria, boxed warnings, and focused updates based on FDA safety findings - Pharmacogenomic considerations in drug dosing and selection - Expanded content on new and emerging gene and cellular therapies - Class-wide revisions to standard and established therapies for common disease states including hypertension and diabetes - Expanded content on off-label uses, real world data, and long-term clinical data - New content on new molecular entities (NMEs) and biologic approvals - New oncology off-label determinations based on reviews by the AHFS Oncology Expert Committee Content licensed from printed ISBN 10: 1585287776 Content licensed from printed ISBN 13: 9781585287772 SUBSCRIPTION : Please purchase a yearly auto-renewing subscription to receive content access and available updates. Yearly auto-renewing payments- $99.99 Payment will be charged to your iTunes Account at confirmation of purchase. Subscription automatically renews unless auto-renew is turned off at least 24-hours before the end of the current period. Subscription may be managed by the user and auto-renewal can be disabled at any time by going to your device “Settings” and tapping “iTunes & App Store”. Any unused portion of a free trial period will be forfeited when you purchase a subscription, where applicable." Privacy Policy - https://www.skyscape.com/terms-of-service/privacypolicy.aspx Terms and Conditions - https://www.skyscape.com/terms-of-service/licenseagreement.aspx https://www.skyscape.com/index/privacy.aspx Editor(s): American Society of Health-System Pharmacists, Inc. Publisher: American Society of Health-System Pharmacists, Inc.